CTOs on the Move

Aprilog

www.aprilog.com

 
Aprilog is a San Mateo, CA-based company in the Computers and Electronics sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aprilog.com
  • 422 Peninsula Ave
    San Mateo, CA USA 94401
  • Phone: 650.375.0409

Executives

Name Title Contact Details

Similar Companies

Endwave Corporation

Endwave Corporation is a San Jose, CA-based company in the Computers and Electronics sector.

Wolverine Trading LP

Wolverine Trading LP is a Chicago, IL-based company in the Computers and Electronics sector.

TT Electronics plc

TT Electronics is a global provider of engineered electronics for performance critical applications. They engineer and manufacture electronics that sense, manage power, connect devices for OEMs in Medical, Aerospace, Defence, Automation and Electrifica...

STMicroelectronics

At ST, we are 46,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An independent device manufacturer, we work with our 100,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of the Internet of Things and 5G technology.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.